Article

FDA approves CrystaLens, first accommodating IOL

Eyeonics inc. (formerly C&C Vision) received FDA approval to marketthe CrystaLens, the first accommodating IOL that allows patients to focusautomatically and seamlessly at all distances.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
March 20th 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Investigators highlight the risk of misdiagnosing geographic atrophy
March 19th 2025

Investigators highlight the risk of misdiagnosing geographic atrophy

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
March 19th 2025

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US
March 18th 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US

© 2025 MJH Life Sciences

All rights reserved.